文献速递炎症性肠病肝病

儿童原发性硬化性胆管炎合并IBD:临床活动轻但亚临床炎症和生长障碍更常见

Primary Sclerosing Cholangitis in Children With Inflammatory Bowel Diseases Is Associated With Milder Clinical Activity But More Frequent Subclinical Inflammation and Growth Impairment.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-09-04

该回顾性研究纳入74例PSC-IBD患儿并按性别、出生日期和IBD类型与2倍对照匹配,比较IBD分布、临床活动及生长情况。PSC-IBD患儿临床缓解率更高、结肠切除或生物制剂使用风险更低,但内镜下缓解率更低且生长障碍更明显。

要点

  • PSC-IBD患儿临床活动轻,但内镜下活动常被症状低估。
  • PSC-IBD患儿结肠切除或生物制剂治疗风险较低。
  • PSC-IBD患儿身高和体重随时间低于对照组。

核心结论

  • 儿童PSC-IBD的IBD特征与成人相似,临床活动轻但亚临床炎症和生长障碍更常见。

研究设计与样本

  • 回顾性研究纳入2000至2018年诊断的74例PSC-IBD患儿,按性别、出生日期和IBD类型与2倍对照匹配。

主要发现

  • PSC-IBD患儿倒灌性回肠炎、全结肠炎、直肠豁免和更严重右侧病变的比例高于对照(P < .05)。
  • PSC-IBD患儿仅用5-ASA的比值比为3.04(95%CI 1.44-6.41),临床缓解的比值比为2.94(95%CI 1.78-4.87)。
  • PSC-IBD患儿结肠切除或生物制剂治疗的风险比为0.24(95%CI 0.12-0.52)。
  • 临床缓解的PSC-IBD患儿内镜下缓解的比值比为0.44(95%CI 0.20-0.96)。
  • PSC-IBD患儿身高和体重随时间低于对照。

临床怎么用

  • 对PSC-IBD患儿不能仅凭症状判断IBD活动度,需考虑内镜评估黏膜炎症。
  • 应关注PSC-IBD患儿的生长情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although inflammatory bowel diseases (IBD) associated with primary sclerosing cholangitis (PSC) have been well characterized in adults, there have been few pediatric studies, and these were small and produced conflicting results. We investigated features of PSC-IBD in children, compared with children with IBD without PSC. METHODS: We performed a retrospective study of 74 children with PSC-IBD, diagnosed from 2000 through 2018, who were each matched with 2 children with ulcerative colitis or IBD-unclassified (controls) based on sex, date of birth, and type of IBD. We compared IBD distribution and clinical activity (remission, medication use, hospitalization, or colectomy) and patient growth between groups. Data were extracted from each hospital contact and analyzed using mixed effects analyses or Cox proportional hazards regression, adjusting for time-dependent medication exposure. RESULTS: Higher proportions of children with PSC-IBD had backwash ileitis, pancolitis, and rectal sparing, and more severe right-sided disease, than controls (P < .05). Patients with PSC-IBD were more likely to be treated with only 5-ASA, compared with controls (odds ratio [OR], 3.04; 95% CI, 1.44-6.41) and to have IBD in clinical remission (OR, 2.94; 95% CI, 1.78-4.87). Risk of colectomy or treatment with a biologic agent was lower in patients with PSC-IBD than controls (hazard ratio, 0.24; 95% CI, 0.12-0.52). However, determination of IBD severity based on symptoms underestimated severity based on endoscopic activity in patients with PSC-IBD. Among patients with IBD in clinical remission, those with PSC were less likely to have endoscopic remission (OR, 0.44; 95% CI, 0.20-0.96). Patients with PSC-IBD were shorter and had lower weight over time, compared with controls. CONCLUSIONS: In a retrospective study, we found that features of IBD differed between children with vs without PSC, similar to adults. Despite the mild clinical activity of IBD in patients with PSC, lack of symptoms does not always indicate lack of mucosal inflammation. Children with PSC-IBD have greater growth impairments compared with children with ulcerative colitis or IBD-unclassified.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ricciuto A, Hansen BE, Ngo B, et al. Primary Sclerosing Cholangitis in Children With Inflammatory Bowel Diseases Is Associated With Milder Clinical Activity But More Frequent Subclinical Inflammation and Growth Impairment. Clin Gastroenterol Hepatol. 2019. PMID: 31493578. doi:10.1016/j.cgh.2019.08.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。